TBPH (Theravance Biopharma) Cyclically Adjusted FCF per Share: $-2.24 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TBPH Theravance Biopharma Inc TBPH
72 GF Score
Price $16.85
GF Value $18.67
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Theravance Biopharma Cyclically Adjusted FCF per Share?

Theravance Biopharma TBPH 72 Cyclically Adjusted FCF per Share is $-2.24 as of Mar. 2026. GuruFocus rates TBPH with a GF Score™ of 72/100 and a GF Value™ of $18.67 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Theravance Biopharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was $1.429. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-2.24 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 18.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Theravance Biopharma was 18.00% per year. The lowest was 18.00% per year. And the median was 18.00% per year.

As of today (2026-07-30), Theravance Biopharma's current stock price is $16.85. Theravance Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-2.24. Theravance Biopharma's Cyclically Adjusted Price-to-FCF of today is .


Theravance Biopharma  (NAS:TBPH) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Theravance Biopharma Cyclically Adjusted FCF per Share Related Terms


Theravance Biopharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Theravance Biopharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theravance Biopharma Cyclically Adjusted FCF per Share Chart

Theravance Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -4.42 -4.11 -3.51 -2.44

Theravance Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.23 -2.66 -2.56 -2.44 -2.24

TBPH vs ABUS, SANA, ANNX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Theravance Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theravance Biopharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Cyclically Adjusted Price-to-FCF falls into.


TBPH
72GF Score
Theravance Biopharma Inc TBPH
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theravance Biopharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theravance Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.429/330.2130*330.2130
=1.429

Current CPI (Mar. 2026) = 330.2130.

Theravance Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.738 241.018 -1.011
201609 -0.276 241.428 -0.377
201612 -0.575 241.432 -0.786
201703 -0.981 243.801 -1.329
201706 -0.866 244.955 -1.167
201709 -1.200 246.819 -1.605
201712 -0.840 246.524 -1.125
201803 0.884 249.554 1.170
201806 -1.164 251.989 -1.525
201809 -0.937 252.439 -1.226
201812 -0.984 251.233 -1.293
201903 -1.500 254.202 -1.949
201906 -0.875 256.143 -1.128
201909 -0.800 256.759 -1.029
201912 -1.170 256.974 -1.503
202003 -0.943 258.115 -1.206
202006 -0.886 257.797 -1.135
202009 -1.249 260.280 -1.585
202012 -1.038 260.474 -1.316
202103 -1.111 264.877 -1.385
202106 -0.765 271.696 -0.930
202109 -0.632 274.310 -0.761
202112 -0.579 278.802 -0.686
202203 -0.350 287.504 -0.402
202206 -0.195 296.311 -0.217
202209 -0.292 296.808 -0.325
202212 -1.846 296.797 -2.054
202303 -0.193 301.836 -0.211
202306 -0.234 305.109 -0.253
202309 -0.048 307.789 -0.051
202312 -0.031 306.746 -0.033
202403 -0.023 312.332 -0.024
202406 -0.091 314.175 -0.096
202409 -0.106 315.301 -0.111
202412 -0.022 315.605 -0.023
202503 0.866 319.799 0.894
202506 4.102 322.561 4.199
202509 -0.125 324.800 -0.127
202512 -0.114 324.054 -0.116
202603 1.429 330.213 1.429

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-2.24 mean?
Theravance Biopharma (TBPH) has a Cyclically Adjusted FCF per Share of $-2.24 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Theravance Biopharma and its competitors.
Is Theravance Biopharma's Cyclically Adjusted FCF per Share too high?
Theravance Biopharma's current Cyclically Adjusted FCF per Share is $-2.24. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's Cyclically Adjusted FCF per Share compare to ABUS and SANA?
Theravance Biopharma's Cyclically Adjusted FCF per Share of $-2.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Theravance Biopharma and its competitors. Theravance Biopharma's current Cyclically Adjusted FCF per Share is $-2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (TBPH) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.67, compared to a current price of $16.85 — trading 9.7% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $-2.24. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Theravance Biopharma (TBPH), the current Cyclically Adjusted FCF per Share is $-2.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Theravance Biopharma (TBPH) Overvalued in 2026?

Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued. The current stock price of $16.85 is trading 9.7% below its estimated GF Value™ of $18.67. GuruFocus considers Theravance Biopharma to be Modestly Undervalued.

Key valuation signals for TBPH:

  • Cyclically Adjusted FCF per Share: $-2.24
  • GF Value™: $18.67 vs. price of $16.85 (9.7% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the TBPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Theravance Biopharma Business Description

Other Exchanges 0TB:Germany
Address C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA, USA, 94080
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score

Get the complete analysis for TBPH

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.85
Price
$18.67
GF Value